COMP <GO>
LXRX vs MRK // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Lexicon Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: LXRX 2
— MRK 8
■ METRIC PARITY
LAST: $1.48 (-0.34%) • MKT CAP: $658.5M
options-implied-move
—
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LXRX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LXRX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 74.80% | +21.20 | LXRX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -31.50% | 20.70% | -52.20 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -10.30% | 3.42% | -13.72 | MRK | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.10% | -88.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 1.30% | +178.70 | LXRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.19 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.0 | 51.7 | -15.70 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $658.5M | $361.02B | -$360.36B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LXRX REV | MRK REV | LXRX GROSS % | MRK GROSS % | LXRX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $49.8M | $65.01B | 98.0% | 74.8% | -$67.9M | $12.36B |
| FY 2024 | $6.0M | $64.17B | 89.7% | 76.3% | -$179.8M | $18.10B |
| FY 2023 | $1.1M | $60.12B | — | — | -$161.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LXRX // BETA —
MRK // BETA 0.92